Download PDF
Viszeralchirurgie 2005; 40(4): 255-259
DOI: 10.1055/s-2005-836754
Originalarbeit

© Georg Thieme Verlag Stuttgart · New York

Minimal residuale Tumorerkrankung beim Ösophaguskarzinom

Minimal Residual Disease in Esophageal CancerB.-C. Link1 , J. R. Izbicki1 , E. F. Yekebas1
  • 1Klinik und Poliklinik für Allgemein-, Viszeral- und Thoraxchirurgie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
Further Information

Publication History

Publication Date:
13 September 2005 (online)

    Permissions and Reprints

Zusammenfassung

Obgleich mikrodisseminierte Tumorzellen in Lymphknoten oder im Knochenmark durch verschiedene Methoden nachgewiesen werden können, ist deren biologische und klinische Relevanz für die Tumorerkrankung nicht restlos geklärt. Die Datenlage hierzu beim Ösophaguskarzinom ist teilweise inkongruent. Letztlich zeigt sich, dass mikrometastatische Tumorzellen in Lymphknoten eine Tumorzellverbreitung repräsentieren, die mit einem signifikant schlechteren Überleben der Patienten verbunden ist und durch das klinisch-pathologische Staging nicht abgebildet wird. Die Wertung von Tumorzellen im Knochenmark ist aufgrund der Heterogenität der Nachweisverfahren und der damit verbundenen diffizilen Validierung insbesondere im Hinblick auf eine klinische Nutzung, z. B. im präoperativen Staging, mit erheblichen Unwägbarkeiten verbunden.

Abstract

Although microdisseminated cancer cells in lymph nodes and in bone marrow can be detected by a variety of methods, their biological and clinical relevance remains unclear. The following article focusing on minimal residual disease in esophageal cancer illustrates and debates numerous publications with reference to this issue. In conclusion, micometastatic cancer cells in lymph nodes indicate systemic spread of disease not reflected by conventional clinical and histological staging, hereby resulting in significantly impaired survival of patients. The detection of cancer cells in bone marrow is clouded by the heterogeneity of their analytic assessment. Consequently, its diagnostic validity seems to be arguable in terms of introduction into clinical practice, e. g. preoperative staging.

Schlüsselwörter

minimal residuale Tumorerkrankung - Mikrometastasen - Mikrodisseminierung - Ösophaguskarzinom - Staging

Key words

minimal residual disease - micrometastasis - micodissemination - esophageal cancer - staging

Literatur

  • 1 Gearhart P J, Sigal N H, Klinman N R. Production of antibodies of identical idiotype but diverse immunoglobulin classes by cells derived from a single stimulated B cell.  Proc Natl Acad Sci U S A. 1975;  72 1707-1711
    PubMedGoogle Scholar
  • 2 Fisher E R, Swamidoss S, Lee C H, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cancer.  Cancer. 1978;  42 2025-2031
    PubMedGoogle Scholar
  • 3 Pickren J W. Significance of occult metastases. A study of breast cancer.  Cancer. 1961;  14 1266-1271
    PubMedGoogle Scholar
  • 4 Friedman S, Bertin F, Mouriesse H. et al . Importance of tumor cells in axillary node sinus margins (‘clandestine’ metastases) discovered by serial sectioning in operable breast carcinoma.  Acta Oncol. 1988;  27 483-487
    PubMedGoogle Scholar
  • 5 Rosen P P, Saigo P E, Braun D W, Weathers E, Fracchia A A, Kinne D W. Axillary micro- and macrometastases in breast cancer: prognostic significance of tumor size.  Ann Surg. 1981;  194 585-591
    PubMedGoogle Scholar
  • 6 Yoshinaka H, Shimazu H, Natsugoe S. et al . [Histopathological features of the lymph node metastases in patients with thoracic esophageal cancer].  Nippon Geka Gakkai Zasshi. 1992;  93 1289-1296
    PubMedGoogle Scholar
  • 7 Komukai S, Nishimaki T, Watanabe H, Ajioka Y, Suzuki T, Hatakeyama K. Significance of immunohistochemically demonstrated micrometastases to lymph nodes in esophageal cancer with histologically negative nodes.  Surgery. 2000;  127 40-46
    CrossrefPubMedGoogle Scholar
  • 8 International (Ludwig) Breast Cancer Study Group . Prognostic importance of occult axillary lymph node micrometastases from breast cancers.  Lancet. 1990;  335 1565-1568
    PubMedGoogle Scholar
  • 9 Latza U, Niedobitek G, Schwarting R, Nekarda H, Stein H. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial.  J Clin Pathol. 1990;  43 213-219
    PubMedGoogle Scholar
  • 10 Passlick B, Izbicki J R, Kubuschok B. et al . Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer.  J Clin Oncol. 1994;  12 1827-1832
    PubMedGoogle Scholar
  • 11 Byrne J, Waldron R, McAvinchey D, Dervan P. The use of monoclonal antibodies for the histopathological detection of mammary axillary micrometastases.  Eur J Surg Oncol. 1987;  13 409-411
    PubMedGoogle Scholar
  • 12 Bussolati G, Gugliotta P, Morra I, Pietribiasi F, Berardengo E. The immunohistochemical detection of lymph node metastases from infiltrating lobular carcinoma of the breast.  Br J Cancer. 1986;  54 631-636
    PubMedGoogle Scholar
  • 13 Stahel R A, Mabry M, Skarin A T, Speak J, Bernal S D. Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody.  J Clin Oncol. 1985;  3 455-461
    PubMedGoogle Scholar
  • 14 Redding W H, Coombes R C, Monaghan P. et al . Detection of micrometastases in patients with primary breast cancer.  Lancet. 1983;  2 1271-1274
    PubMedGoogle Scholar
  • 15 Coombes R C, Dearnaley D P, Buckman R. et al . Detection of bone metastases in patients with breast cancer.  Invasion Metastasis. 1982;  2 177-184
    PubMedGoogle Scholar
  • 16 Schlimok G, Funke I, Holzmann B. et al . Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies.  Proc Natl Acad Sci USA. 1987;  84 8672-8676
    PubMedGoogle Scholar
  • 17 Ross A A, Miller G W, Moss T J. et al . Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer.  Bone Marrow Transplant. 1995;  15 929-933
    PubMedGoogle Scholar
  • 18 Hay F G, Ford A, Leonard R C. Clinical applications of immunocytochemistry in the monitoring of the bone marrow in small cell lung cancer (SCLC).  Int J Cancer Suppl. 1988;  2 8-10
    PubMedGoogle Scholar
  • 19 Deguchi T, Yang M, Ehara H. et al . Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer.  Br J Cancer. 1997;  75 634-638
    CrossrefPubMedGoogle Scholar
  • 20 Pecorini F, Veneziano M, Framarino Dei Malatesta M L. et al . Considerations on the prognostic significance of bone marrow micrometastases in breast cancer.  Eur J Gynaecol Oncol. 1993;  14 501-505
    PubMedGoogle Scholar
  • 21 Izbicki J R, Hosch S B, Pichlmeier U. et al . Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer.  N Engl J Med. 1997;  337 1188-1194
    CrossrefPubMedGoogle Scholar
  • 22 Heiss M M, Allgayer H, Gruetzner K U, Babic R, Jauch K W, Schildberg F W. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.  Ann Surg. 1997;  226 736-744
    CrossrefPubMedGoogle Scholar
  • 23 Neville A M. Breast cancer micrometastases in lymph nodes and bone marrow are prognostically important.  Ann Oncol. 1991;  2 13-14
    PubMedGoogle Scholar
  • 24 Untch M, Harbeck N, Eiermann W. [Micrometastases in bone marrow at the time of primary treatment of breast cancer: a new prognostic criterion?].  Gynakol Rundsch. 1989;  29 (Suppl 2) 231-233
    PubMedGoogle Scholar
  • 25 Passlick B, Izbicki J R, Kubuschok B, Thetter O, Pantel K. Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis.  Ann Thorac Surg. 1996;  61 177-182
    CrossrefPubMedGoogle Scholar
  • 26 Izbicki J R, Hosch S B. Minimal dissemination of solid epithelial tumours: impact on staging and therapeutic strategy.  Br J Surg. 1997;  84 897-898
    PubMedGoogle Scholar
  • 27 Pantel K, Cote R J, Fodstad O. Detection and clinical importance of micrometastatic disease.  J Natl Cancer Inst. 1999;  91 1113-1124
    CrossrefPubMedGoogle Scholar
  • 28 Relihan N, McGreal G, Kelly J, Ryan D, O'Sullivan G C, Redmond H P. Combined sentinel lymph-node mapping and bone-marrow micrometastatic analysis for improved staging in breast cancer.  Lancet. 1999;  354 129-130
    CrossrefPubMedGoogle Scholar
  • 29 Lerut T, De Leyn P, Coosemans W, Van Raemdonck D, Scheys I, LeSaffre E. Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy.  Ann Surg. 1992;  216 583-590
    PubMedGoogle Scholar
  • 30 Hulscher J B, van Sandick J W, de Boer A G. et al . Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.  N Engl J Med. 2002;  347 1662-1669
    CrossrefPubMedGoogle Scholar
  • 31 Stein H J, Siewert J R. Improved prognosis of resected esophageal cancer.  World J Surg. 2004;  28 520-525
    PubMedGoogle Scholar
  • 32 Veronesi U, Galimberti V, Mariani L. et al . Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection.  Eur J Cancer. 2005;  41 231-237
    CrossrefPubMedGoogle Scholar
  • 33 Kapteijn B A, Nieweg O E, Petersen J L. et al . Identification and biopsy of the sentinel lymph node in breast cancer.  Eur J Surg Oncol. 1998;  24 427-430
    CrossrefPubMedGoogle Scholar
  • 34 Albertini J J, Cruse C W, Rapaport D. et al . Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma.  Ann Surg. 1996;  223 217-224
    CrossrefPubMedGoogle Scholar
  • 35 Yoshino I, Yokoyama H, Yano T. et al . Skip metastasis to the mediastinal lymph nodes in non-small cell lung cancer.  Ann Thorac Surg. 1996;  62 1021-1025
    CrossrefPubMedGoogle Scholar
  • 36 Ducci M, Appetecchia M, Marzetti M. Neck dissection for surgical treatment of lymphnode metastasis in papillary thyroid carcinoma.  J Exp Clin Cancer Res. 1997;  16 33-335
    PubMedGoogle Scholar
  • 37 Hosch S B, Stoecklein N H, Pichlmeier U. et al . Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance.  J Clin Oncol. 2001;  19 1970-1975
    PubMedGoogle Scholar
  • 38 Natsugoe S, Mueller J, Stein H J, Feith M, Hofler H, Siewert J R. Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma: frequency, associated tumor characteristics, and impact on prognosis.  Cancer. 1998;  83 858-866
    CrossrefPubMedGoogle Scholar
  • 39 Mueller J D, Stein H J, Oyang T. et al . Frequency and clinical impact of lymph node micrometastasis and tumor cell microinvolvement in patients with adenocarcinoma of the esophagogastric junction.  Cancer. 2000;  89 1874-1882
    CrossrefPubMedGoogle Scholar
  • 40 Greenson J K, Isenhart C E, Rice R, Mojzisik C, Houchens D, Martin E W. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival.  Cancer. 1994;  73 563-569
    PubMedGoogle Scholar
  • 41 Trojani M, de Mascarel I, Bonichon F, Coindre J M, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance.  Br J Cancer. 1987;  55 303-306
    PubMedGoogle Scholar
  • 42 Hosch S B, Knoefel W T, Metz S. et al . Early lymphatic tumor cell dissemination in pancreatic cancer: frequency and prognostic significance.  Pancreas. 1997;  15 154-159
    PubMedGoogle Scholar
  • 43 Sakata K. Ueber die Lymphgefässe des: Oesophagus und über seine regionären Lymphdrüsen mit Berücksichtigung der Verbreitung des Carcinoms.  Mitt Grenzgeb Medizin. 1903;  11 629-656
    PubMedGoogle Scholar
  • 44 Junker K, Gumprich T, Muller K M. [Discontinuous lymph node metastases (“skipping”) in malignant lung tumors].  Chirurg. 1997;  68 596-599
    CrossrefPubMedGoogle Scholar
  • 45 van de Ven C, De Leyn P, Coosemans W, Van Raemdonck D, Lerut T. Three-field lymphadenectomy and pattern of lymph node spread in T3 adenocarcinoma of the distal esophagus and the gastro-esophageal junction.  Eur J Cardiothorac Surg. 1999;  15 769-773
    CrossrefPubMedGoogle Scholar
  • 46 Akiyama H, Tsurumaru M, Kawamura T, Ono Y. Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement.  Ann Surg. 1981;  194 438-446
    PubMedGoogle Scholar
  • 47 Zgajnar J, Besic N, Podkrajsek M, Hertl K, Frkovic-Grazio S, Hocevar M. Minimal risk of macrometastases in the non-sentinel axillary lymph nodes in breast cancer patients with micrometastatic sentinel lymph nodes and preoperatively ultrasonically uninvolved axillary lymph nodes.  Eur J Cancer. 2005;  41 244-248
    CrossrefPubMedGoogle Scholar
  • 48 Wong S L, Kattan M W, McMasters K M, Coit D G. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system.  Ann Surg Oncol. 2005;  12 282-288
    CrossrefPubMedGoogle Scholar
  • 49 Lamb P J, Griffin S M, Burt A D, Lloyd J, Karat D, Hayes N. Sentinel node biopsy to evaluate the metastatic dissemination of oesophageal adenocarcinoma.  Br J Surg. 2005;  92 60-67
    CrossrefPubMedGoogle Scholar
  • 50 Nomura T, Onda M, Miyashita M. et al . Wide-spread distribution of sentinel lymph nodes in esophageal cancer.  J Nippon Med Sch. 2001;  68 393-396
    CrossrefPubMedGoogle Scholar
  • 51 Matsubara T, Ueda M, Kaisaki S. et al . Localization of initial lymph node metastasis from carcinoma of the thoracic esophagus.  Cancer. 2000;  89 1869-1873
    CrossrefPubMedGoogle Scholar
  • 52 Kitagawa Y, Fujii H, Mukai M. et al . [The validity of the sentinel node concept in gastrointestinal cancers].  Nippon Geka Gakkai Zasshi. 2000;  101 315-319
    PubMedGoogle Scholar
  • 53 Kato H, Miyazaki T, Nakajima M. et al . Sentinel lymph nodes with technetium-99m colloidal rhenium sulfide in patients with esophageal carcinoma.  Cancer. 2003;  98 932-939
    CrossrefPubMedGoogle Scholar
  • 54 Yasuda S, Shimada H, Chino O. et al . Sentinel lymph node detection with 99mTc tin colloids in patients with esophagogastric cancer.  Jpn J Clin Oncol. 2003;  33 68-72
    CrossrefPubMedGoogle Scholar
  • 55 Braun S, Pantel K. Micrometastatic bone marrow involvement: detection and prognostic significance.  Med Oncol. 1999;  16 154-165
    PubMedGoogle Scholar
  • 56 Inoue H, Kajiyama Y, Tsurumaru M. Clinical significance of bone marrow micrometastases in esophageal cancer.  Dis Esophagus. 2004;  17 328-332
    CrossrefPubMedGoogle Scholar
  • 57 Bonavina L, Soligo D, Quirici N. et al . Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia.  Surgery. 2001;  129 15-22
    CrossrefPubMedGoogle Scholar

PD Dr. E. F. Yekebas

Klinik für Allgemein-, Viszeral- und Thoraxchirurgie · Universitätsklinikum Hamburg-Eppendorf

Martinistr. 52

20252 Hamburg

Email: yekebas@uke.uni-hamburg.de

      >